Tsukahara, Tomohide http://orcid.org/0000-0002-3678-4359
Watanabe, Kazue
Murata, Kenji
Takahashi, Akari
Mizushima, Emi
Shibayama, Yuji
Kameshima, Hidekazu
Hatae, Ryo
Ohno, Yasuo
Kawahara, Rituko
Murai, Aiko
Nakatsugawa, Munehide
Kubo, Terufumi
Kanaseki, Takayuki
Hirohashi, Yoshihiko
Terui, Takeshi
Asanuma, Hiroko
Hasegawa, Tadashi
Sato, Noriyuki
Torigoe, Toshihiko
Funding for this research was provided by:
KAKENHI (16H05451, 17H01540)
Takeda Science Foundation (2018-Kenkyu-Shorei)
Ono Cancer Research Fund (2017-3)
Article History
Received: 21 April 2019
Accepted: 13 December 2019
First Online: 18 December 2019
Compliance with ethical standards
:
: Tomohide Tsukahara, Yoshihiko Hirohashi, Takayuki Kanaseki, Munehide Nakatsugawa, Terufumi Kubo, and Toshihiko Torigoe received financial support through collaboration with Ono Pharmaceutical Co., Ltd. Tomohide Tsukahara, Yoshihiko Hirohashi, Takayuki Kanaseki, and Toshihiko Torigoe received financial support through collaboration with Medical Biological Laboratories Co., Ltd. The authors declare that there are no other conflicts of interest.
: This study was performed in accordance with the guidelines established by the Declaration of Helsinki and approved by the Ethics Committees of Higashi-Sapporo Hospital (260630) and Sapporo Medical University (282-156).
: The patient and his family provided written informed consent for the use of tumor and blood samples in our research and for publication. Blood from healthy donors was collected by the Japanese Red Cross Hokkaido Block Blood Center after obtaining informed consent from the donors for research purposes.
: C1R-A24 cells (C1R cells transfected with HLA-A*24:02 cDNA) were kindly provided by Dr. M. Takiguchi (Kumamoto University School of Medicine, Japan). C1R-A24 cells were authenticated by HLA typing.